secwatch / observer
8-K filed November 16, 2023, 6:59 PM ET ticker IDXG CIK 0001054102
leadership confidence high sentiment neutral materiality 0.20

Director Edward Chan resigns from Interpace board; annual meeting results filed

INTERPACE BIOSCIENCES, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Edward Chan

Director
IDXG · INTERPACE BIOSCIENCES, INC.
Effective
2023-11-15
Filed
November 16, 2023, 6:59 PM ET
On November 15, 2023, Edward Chan, a Class II director designated by 1315 Capital II, L.P. to the board of directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”), provided notice to the Company of his resignation from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Edward Chan resigned as Director at INTERPACE BIOSCIENCES, INC..

Action
resigned
Role
Director
Exact text from the filing
On November 15, 2023, Edward Chan, a Class II director designated by 1315 Capital II, L.P. to the board of directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”), provided notice to the Company of his resignation from the Board, effective immediately.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on a resolution approving the compensation of our named executive officers. at the 2023-11-14 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-11-14
Exact text from the filing
A non-binding advisory vote on a resolution approving the compensation of our named executive officers. For Against Abstain Broker Non-Vote 9,177,922 73,760 85,887 1,615,870
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on the frequency of executive compensation advisory votes. at the 2023-11-14 meeting.

Proposal
say on pay frequency
Outcome
passed
Meeting
2023-11-14
Exact text from the filing
A non-binding advisory vote on the frequency of executive compensation advisory votes. Every One Year Every Two Years Every Three Years Abstain Broker Non-Vote 202,362 10,069 9,089,392 35,746 1,615,870
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTERPACE BIOSCIENCES, INC. shareholders approved Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. at the 2023-11-14 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-11-14
Exact text from the filing
Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. Name For Withhold Broker Non-Vote Thomas W. Burnell 9,294,768 42,801 1,615,870 Joseph Keegan, Ph.D. 9,191,329 146,240 1,615,870
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-11-14 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-11-14
Exact text from the filing
Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Vote 10,907,312 42,734 3,393 0
View on SEC.gov

Browse all shareholder votes →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR
accession 0001493152-23-041662
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.